| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 303 | 344 | 360 | 392 | 335 | 356 | 350 | 309 | 353 | 404 | 435 | 454 | 412 | 405 | 105 | 367 | 337 | 342 | 402 | 385 | 354 | 426 | 212 | 301 | 364 | 347 | 302 | 279 | 320 |
| Expenses | 263 | 295 | 294 | 321 | 267 | 283 | 266 | 247 | 265 | 300 | 321 | 345 | 315 | 330 | 199 | 349 | 318 | 311 | 350 | 332 | 333 | 393 | 436 | 412 | 322 | 286 | 243 | 228 | 262 |
| EBITDA | 40 | 49 | 66 | 71 | 68 | 73 | 84 | 62 | 88 | 104 | 114 | 109 | 97 | 75 | -94 | 18 | 20 | 31 | 52 | 53 | 21 | 34 | -224 | -111 | 43 | 62 | 59 | 51 | 58 |
| Operating Profit % | 13 % | 14 % | 17 % | 17 % | 19 % | 19 % | 23 % | 17 % | 24 % | 25 % | 25 % | 22 % | 22 % | 18 % | -98 % | 3 % | 4 % | 8 % | 11 % | 13 % | 5 % | 8 % | -106 % | -38 % | 12 % | 18 % | 19 % | 17 % | 18 % |
| Depreciation | 19 | 19 | 21 | 23 | 23 | 24 | 24 | 24 | 26 | 28 | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 29 | 28 | 27 | 26 | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 |
| Interest | 18 | 20 | 23 | 22 | 19 | 20 | 19 | 20 | 20 | 19 | 21 | 25 | 19 | 17 | 18 | 22 | 23 | 22 | 24 | 22 | 25 | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 |
| Profit Before Tax | 3 | 9 | 22 | 26 | 27 | 29 | 41 | 18 | 42 | 57 | 66 | 57 | 50 | 30 | -140 | -31 | -31 | -19 | 1 | 5 | -29 | -17 | -275 | -167 | -14 | 8 | 8 | -2 | 11 |
| Tax | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -33 | -15 | -9 | 0 | 1 | -10 | 0 | 0 | 89 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 3 | 9 | 22 | 26 | 27 | 29 | 41 | 18 | 42 | 57 | 66 | 57 | 50 | 30 | -140 | 2 | -17 | -10 | 0 | 4 | -19 | -17 | -275 | -255 | -14 | 8 | 8 | -2 | 11 |
| EPS in ₹ | 0.23 | 3.47 | 8.96 | 10.17 | 10.29 | 11.21 | 16.00 | 6.78 | 15.75 | 19.21 | 18.47 | 15.57 | 13.95 | 8.27 | -38.93 | 0.53 | -4.56 | -2.77 | 0.12 | 1.05 | -5.43 | -4.77 | -72.07 | -70.93 | -3.50 | 2.54 | 2.03 | -0.93 | 2.46 |
Solara Active Pharma Sciences
Solara Active Pharma Sciences
657.25
-39.75
(-5.70%)
Q1 Quarterly Results are out. Check out the updated financials2 days ago
View
Market Cap
2,376.24 Cr
EPS
0.14
PE Ratio
102.63
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
882.80
52 Week Low
442.80
PB Ratio
2.31
Debt to Equity
0.83
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Solara Active Pharma Sciences Reports No Deviation in Rights Issue Fund Utilization for Quarter Ended June 30, 20253 days ago
Solara Active Pharma Sciences Limited confirmed no deviation in the utilization of funds raised through its Rights Issue for the quarter ended June 30, 2025. The company raised Rs. 149.49 crores on May 6, 2025, with funds allocated for repayment of borrowings (Rs. 115 crores) and general corporate purposes (Rs. 23.27 crores). Out of the total funds raised, Rs. 138.27 crores were utilized during the quarter, while Rs. 0.26 crores remained in the escrow account and Rs. 10.96 crores in the monitoring account for future utilization. The Rights Issue involved 1,19,98,755 partly paid Rights Shares at Rs. 131.25 per share, with CRISIL Ratings Limited serving as the monitoring agency. The company's Audit Committee reviewed and approved the utilization statement without any comments.
Solara Active Pharma Reports Strong Q1 FY26 Results with 15% Revenue Growth and Positive Earnings3 days ago
Solara Active Pharma Sciences Limited reported quarterly results for the period ended June 30, 2025, showing revenue of Rs. 319.15 crores, up 15% quarter-on-quarter from Rs. 273.01 crores. The company achieved a profit of Rs. 10.52 crores compared to a loss of Rs. 13.46 crores in the same quarter last year. Gross margins improved to 54.1% from 44.5% year-on-year, while EBITDA margins reached 18.0% versus 11.6% in the previous year. The company reduced gross debt from Rs. 7,760 million to Rs. 6,327 million during the quarter. Earnings per share turned positive at Rs. 2.46 compared to a loss of Rs. 3.50 per share in the corresponding quarter. The Board also appointed Mr. Rajesh Patro as Chief Risk Officer. Regulated markets constituted 77% of total revenues, and the company expects to raise Rs. 134.99 crores through pending rights issue calls.
Solara Active Pharma Sciences delivered improved quarterly results with EBITDA rising to 570 million rupees from 419 million rupees year-over-year. The company's EBITDA margin expanded significantly to 17.87% compared to 11.5% in the same period last year. The pharmaceutical company turned profitable with a consolidated net profit of 105 million rupees, marking a turnaround from a loss of 135 million rupees in the previous year. However, revenue declined to 3.2 billion rupees from 3.63 billion rupees year-over-year.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,702.20 | #1 4,08,414.80 | 35.57 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 55.97 | |
6,584.00 | 1,74,784.51 | 80.22 | 9,712.00 | 0.89 | 2,191 | 23.05 | 40.37 | |
1,572.00 | 1,26,971.67 | 22.93 | 28,409.50 | 7.12 | 5,291 | 9.88 | 70.77 | |
3,622.90 | 1,21,969.00 | 63.65 | 11,539.40 | 6.99 | 1,911 | 19.91 | 72.46 | |
1,287.40 | 1,07,442.68 | #1 18.77 | 33,741.20 | 16.73 | 5,725 | 1.26 | 54.50 | |
2,541.60 | 1,04,899.14 | 61.83 | 12,744.20 | 19.57 | 2,007 | -10.91 | 52.39 | |
980.10 | 98,620.99 | 21.15 | 23,511.00 | 13.82 | 4,615 | -0.19 | 54.96 | |
1,960.50 | 89,535.15 | 27.44 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 53.75 | |
32,895.00 | 69,899.58 | 50.72 | 6,684.70 | 10.80 | 1,414 | 27.83 | 42.22 | |
1,127.00 | 65,456.34 | 18.86 | 31,378.10 | 17.55 | 3,366 | -0.50 | 47.15 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
-11.74 %
Net Income Growth
2,442.60 %
Cash Flow Change
-30.32 %
ROE
3,990.54 %
ROCE
-1,472.62 %
EBITDA Margin (Avg.)
-165.04 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,822 | 1,960 | 2,154 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,109 |
| Current Assets | 608 | 648 | 672 | 1,058 | 1,239 | 1,188 | 801 | 729 |
| Capital Work in Progress | 72 | 40 | 41 | 88 | 239 | 239 | 256 | 280 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 318 |
| Other Assets | 663 | 702 | 716 | 1,144 | 1,350 | 1,295 | 825 | 0 |
| Total Liabilities | 1,822 | 1,960 | 2,154 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
| Current Liabilities | 738 | 656 | 730 | 789 | 1,063 | 1,101 | 1,243 | 944 |
| Non Current Liabilities | 315 | 344 | 333 | 232 | 354 | 296 | 172 | 191 |
| Total Equity | 769 | 960 | 1,090 | 1,593 | 1,527 | 1,502 | 937 | 1,094 |
| Reserve & Surplus | 739 | 826 | 963 | 1,553 | 1,489 | 1,464 | 898 | 1,054 |
| Share Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 32 | 30 | -20 | 142 | -151 | -38 | -0 |
| Investing Activities | -86 | -113 | -359 | -106 | -243 | -81 | -4 |
| Operating Activities | 49 | 166 | 242 | 156 | -242 | 156 | 109 |
| Financing Activities | 68 | -23 | 97 | 93 | 334 | -113 | -106 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 44.11 % | 41.07 % | 41.07 % | 39.51 % | 39.71 % | 40.40 % | 40.40 % | 40.40 % | 40.97 % | 39.31 % | 37.19 % | 30.49 % | 30.49 % | 37.27 % | 37.27 % | 37.23 % | 37.94 % | 42.01 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 15.80 % | 14.00 % | 14.25 % | 14.67 % | 14.63 % | 14.25 % |
| DIIs | 3.72 % | 6.18 % | 5.55 % | 5.38 % | 3.39 % | 2.85 % | 2.56 % | 3.01 % | 2.22 % | 1.75 % | 1.75 % | 1.71 % | 2.97 % | 2.83 % | 3.38 % | 3.19 % | 2.61 % | 2.62 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 14.76 % | 14.35 % | 13.84 % | 16.36 % | 17.41 % | 16.61 % | 17.28 % | 16.54 % | 16.23 % | 18.06 % | 19.84 % | 20.95 % | 20.15 % | 19.61 % | 18.83 % | 21.93 % | 23.07 % | 23.47 % |
| Others | 37.41 % | 38.40 % | 39.53 % | 38.73 % | 39.48 % | 40.15 % | 39.76 % | 40.04 % | 40.58 % | 40.88 % | 41.22 % | 46.84 % | 30.59 % | 26.29 % | 26.28 % | 22.98 % | 21.74 % | 17.63 % |
| No of Share Holders | 58,907 | 67,197 | 65,449 | 73,000 | 77,228 | 82,710 | 83,319 | 79,149 | 76,325 | 75,417 | 74,473 | 72,918 | 73,912 | 78,617 | 71,882 | 83,148 | 75,791 | 74,334 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 5 | 2 | 7 | 0.00 | 3 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.22 | 0.16 | 1.14 | 0.00 | 0.88 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Jul 2025 |  Quarterly Result Announcement | NA | 25 Jul 2025 | 692.85 | 657.35 |
| 15 May 2025 | Quarterly Result Announcement | NA | 15 May 2025 | 482.35 | 576.30 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 652.85 | 678.80 |
| 21 Oct 2024 | Quarterly Result Announcement | NA | 21 Oct 2024 | 748.90 | 809.60 |
| 20 Sept 2024 |  Annual General Meeting | NA | 20 Sept 2024 | 694.40 | 736.35 |
| 15 May 2024 |  Rights | 1:3 | 15 May 2024 | 465.01 | 503.40 |
| 20 Aug 2021 |  Dividend | ₹ 3.00 /share | 18 Aug 2021 | 1,484.58 | 1,564.11 |
| 25 Mar 2017 |  Change Of Name | NA | 25 Mar 2017 | 0.00 | 0.00 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
3 days agoStatement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended June 30 2025.3 days ago
3 days agoBoard Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30 2025.3 days ago
3 days agoBoard Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30 2025.3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoBoard Meeting Intimation for Quarter Ended June 30 2025 Under SEBI Listing Regulations10 days ago
10 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Jul 03, 2025Dispatch Of First Reminder Notice For Payment Of First Call MoneyJul 02, 2025
Jul 02, 2025Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 2025Appointment Of Internal Auditors Secretarial Auditor And Reappointment Of Cost Auditor.May 15, 2025
May 15, 2025Appointment of Company Secretary and Compliance OfficerMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-RetirementMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 15, 2025
May 15, 2025Statement Of Deviation And VariationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
May 15, 2025Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31 2025May 15, 2025
May 15, 2025Audited Financial Results For The Quarter And Year Ended March 31 2025May 15, 2025
May 15, 2025Announcement Under Regulation 30 - Press ReleaseMay 10, 2025
May 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
May 08, 2025Board Meeting Intimation for Board Meeting IntimationMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 07, 2025
May 07, 2025Board Meeting Outcome for Board Meeting Outcome For The Rights Issue Committee Meeting - Receipt Of First Call MoneyMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Change in Corporate Office AddressMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Change in Registered Office AddressMay 05, 2025
May 05, 2025Incorporation Of Wholly Owned Subsidiary CompanyApr 29, 2025
Apr 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 09, 2025
Apr 09, 2025Notice On The First Call Money Of The Rights Equity Shares.Apr 09, 2025
Apr 09, 2025Board Meeting Outcome for Outcome Of The Rights Issue Committee Meeting_Solara Active Pharma Sciences LimitedApr 02, 2025
Apr 02, 2025Announcement under Regulation 30 (LODR)-Meeting UpdatesApr 02, 2025
Apr 02, 2025Board Meeting Intimation for Rights Issue Committee Meeting To Approve The Notice Of First Call To Be Sent To The Eligible Shareholders.Mar 26, 2025
Mar 26, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Record Date For The Purpose Of Making First Call For Rights Issue Equity SharesMar 26, 2025
Mar 26, 2025Board Meeting Outcome for Intimation Under Regulation 30 And 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Meeting UpdatesMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 21, 2025
Mar 21, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 20, 2025
Mar 20, 2025Board Meeting Intimation for Rights Issue Committee Meeting For Making The First Call Of The Shares Issued On Rights Basis By The Company.Mar 20, 2025
Mar 20, 2025Grant Of ESOP OptionsFeb 21, 2025
Feb 21, 2025Technical Indicators
RSI(14)
Neutral 56.12
ATR(14)
Volatile 33.83
STOCH(9,6)
Neutral 55.17
STOCH RSI(14)
Oversold 16.32
MACD(12,26)
Bearish -4.43
ADX(14)
Very Strong Trend 54.74
UO(9)
Bearish 40.79
ROC(12)
Uptrend But Slowing Down 4.63
WillR(14)
Neutral -63.37
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.15% | 14 | 0.03% | 0.03% | |
 Aditya Birla Sun Life Flexi Cap Fund Direct-Growth | 0.11% | 0 | 0.02% | 0.02% | |
| Aditya Birla Sun Life Manufacturing Equity Fund Direct-Growth | 0.86% | 0 | 0.19% | 0.53% | |
| Aditya Birla Sun Life Mid Cap Direct Fund-Growth | 0.00% | 0 | 0.00% | -0.09% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
